Company

Neurizon

Biotechnology Research Au 11 employees

Employees: 11
Contacts: 3
Emails: 3
Phones: 1

pharmaust.com LinkedIn

Neurizon Overview

Headquarters: Au
Website: pharmaust.com
Industry: Biotechnology Research
Employees: 11
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Pharmaceutical Biotechnology Drug manufacturing Motor Neurone Disease Neurodegenerative diseases Amyotrophic lateral sclerosis

About Neurizon

Neurizon Therapeutics Limited (ASX: NUZ), formerly known as PharmAust, is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon strategy is to accelerate access to effective ALS treatments for patients, while exploring NUZ-001’s potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.

Neurizon Contact Details

People in AeroLeads: 4
With contact data: 3
Email contacts: 3; 75.0% coverage
Phone contacts: 1; 25.0% coverage

Neurizon Org Chart

Sample employees and titles

Name	Title	Location	Contact
Lidija Damjanovic	Strategic Marketing, Omnichannel Campaigns, and Corporate Communications	Manly, New South Wales, Australia	Email
Katie Macfarlane	Pharma Product Development and Commercialization Expert	Washington, District of Columbia, United States	Email Phone
Paul Field		Greater Sydney Area, Australia	Email
Kathryn W.	Chief Regulatory & Market Access Executive - Rare Disease Strategy - Fda, Ema, Tga, Mhra - Board-facing, Patient-centred, Commercially Sharp		View